BioPorto A/S, an in-vitro diagnostics company, provides biomarker tools and antibodies for clinical research in Europe, North America, Asia, and internationally. It offers the neutrophil gelatinase-associated lipocalin test, a quantitative particle-enhanced turbidimetric immunoassay designed to run on automated clinical chemistry analyzers; monoclonal antibodies for scientific, pharmaceutical, and clinical research; and enzyme-linked immunosorbent assay kits, as well as generic rapid assay device for custom lateral flow assays. BioPorto A/S was incorporated in 1917 and is based in Hellerup, Denmark.

Sector

Healthcare

Industry

Medical - Diagnostics & Research

CEO

Eriksen, Peter

Employees

Website

bioporto.com

IPO Date

2000-01-13

Headquarters

Tuborg Havnevej 15, st., Ground Floor, Hellerup, Capital Region of Denmark, 2900, Denmark

Socials

NEWSLETTER

View Data Providers

NEWSLETTER

View Data Providers

Gainify provides tools and content designed to help users explore and understand the world of investing. All information available through our platform is for educational and informational use only. It is not intended as financial, investment or legal advice, and should not be treated as a recommendation or endorsement of any investment approach.
Our content is general in nature and does not account for your personal financial circumstances. Any investment decisions you make are your responsibility. We strongly recommend speaking with a licensed financial advisor or professional before acting on any information found on Gainify. Before using Gainify, please review our Terms of Service.

BioPorto BIOPOR

BioPorto Earnings Call Summary

BioPorto Earnings

Transcripts

Events

About BioPorto A/S

BioPorto
BIOPOR